Anjana RM,Unnikrishnan R,Deepa M,Pradeepa R,Tandon N,Das AK .2023 .Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMRINDIAB-17). Lancet Diabetes Endocrinol, 8587(23) : 00119-5.
Karachaliou F,Simatos G,Simatou A .2020 .The challenges in the development of diabetes prevention and care models in lowincome settings. Front Endocrinol (Lausanne), 11 : 518.
Unnikrishnan R,Anjana RM,Mohan V .2016 .Diabetes mellitus and its complications in India. Nat Rev Endocrinol, 12(6) : 357-70.
Oberoi S,Kansra P .2020 .Economic menace of diabetes in India: a systematic review. Int J Diabetes Dev Ctries, 40(4) : 464-75.
Kumpatla S,Kothandan H,Tharkar S,Viswanathan V. .2013 .The costs of treating long-term diabetic complications in a developing country: a study from India. J Assoc Physicians India, 61(2) : 102-9.
Polonsky WH,Henry RR .2016 .Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence, 10 : 1299-307.
Kalra S,Gupta Y,Sahay R. .2016 .The law of therapeutic parsimony. Indian J Endocrinol Metab, 20(3) : 180008-8210.
Samson SL,Vellanki P,Blonde L,Christofides EA,Galindo RJ,Hirsch IB .2023 .American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract, 02(5) : 305-40.
Diabetes Association Professional Practice American .2024 .Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care, 47(Suppl 1) : S158-78.
Kalra S,Bahendeka S,Sahay R,Ghosh S,Fariduddin Md,Orabi A .2018 .Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - International Task Force. Indian J Endocrinol Metab, 556(1) : 17-57.
.2022 .pdf (cdsco. gov. Recommendations Endocrinology & Metabolism, 26 : 08.
.2022 .Standards of Care in Diabetes-2023 Abridged for Primary Care Providers. Clin Diabetes, 41(1) : 4-31.
.2022 .RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int J Diabetes Dev Ctries, 42(Suppl 1) : 1-143.
.2016 .Cost-efective solutions for the prevention of type 2 diabetes. , : .
Swain SP,Samal S,Sahu KS,Rout SK .2018 .Out-of-pocket expenditure and drug adherence of patients with diabetes in Odisha. J Family Med Prim Care, 24(6) : 18-35.
Kirkman MS,Rowan-Martin MT,Levin R,Fonseca VA,Schmittdiel JA,Herman WH .2015 .Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care, 38(4) : 2098-9.
Aroda VR,Ratner RE .2018 .Metformin and type 2 diabetes prevention. Diabetes Spectr, 31(4) : 0020-42.
Mahabaleshwarkar R,A R .2020 .Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States. Diabetes Res Clin Pract, 172 : 108531.
Vieira IH,Barros LM,Baptista CF,Rodrigues DM,Paiva IM .2022 .Recommendations for practical use of metformin, a central pharmacological therapy in type 2 diabetes. Clin Diabetes, 40(1) : 0043-107.
Young-Hyman D,de Groot M,Hill-Briggs F,Gonzalez JS,Hood K,Peyrot M. .2016 .Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care, 39(12) : 2053-40.
Tan HQM,Chin YH,Ng CH,Liow Y,Devi MK,Khoo CM .2020 .Multidisciplinary team approach to diabetes. An outlook on providers' and patients' perspectives. Prim Care Diabetes, 05(5) : 545-51.
Joyson BS,Jacob MS,Mathew F,Thomas J,Sushilkumar PL .2019 .Identification, assessment, and analysis of the cost-efectiveness of oral hypoglycemic agents for pharmacoeconomic evaluation in a tertiary care teaching hospital. World J Pharm Res, 8(12) : 1229-42.
Singh A,Dutta S,Varma A,Beg M,Kumar H,Kaur A .2016 .A drug utilization and pharmacoeconomic study of anti-diabetic drugs prescribed to type 2 diabetes mellitus patients visiting the medicine outpatient department of a tertiary care hospital of North India. Int J Basic Clin Pharmacol, 5(4) : 2319-2003.
Kodama N,Tahara N,Tahara A,Honda A,Nitta Y,Mizoguchi M .2013 .Efects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. J Clin Endocrinol Metab, 98(11) : 2920-45.
John M,Gopinath D,Kalra S. .2015 .Triple fixed drug combinations in type 2 diabetes. Indian J Endocrinol Metab, 19(3) : 152739-8210.
Banu S,Baburaj A,Johncy N,Chandur VK,Siva S. .2020 .A study on cost analysis in diabetic patients with cardiovascular complications in a tertiary care teaching hospital. Int J Health Sci Res, 10(April2020) : .
ElSayed NA,Aleppo G,Aroda VR,Bannuru RR,Brown FM,Bruemmer D .2023 .Cardiovascular disease and risk management: standards of medical care in diabetes-2023. Diabetes Care, 46(Suppl 1) : S158-90.
Arnett DK,Blumenthal RS,Albert MA,Buroker AB,Goldberger ZD,Hahn EJ .2019 .ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 140(11) : e596-646.
Papazafiropoulou AK,Melidonis A,Antonopoulos S. .2021 .Aspirin in primary prevention of cardiovascular disease in diabetes. Arch Med Sci Atheroscler Dis, 6 : e109-14.
Gillani SW,Syed Sulaiman SA,Menon V,Rahamathullah N,Elshafie RM,Rathore HA .2022 .6): e0270143. PLoS One, 17 : .
ElSayed NA,Aleppo G,Aroda VR,Bannuru RR,Brown FM,Bruemmer D .2023 .9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care, 46(Supplement) : S140-57.
Zhao JZ,Weinhandl ED .2020 .Glucose-lowering medication use in CKD: analysis of US medicare beneficiaries between 2007 and 2016. Kidney Med, 09(2) : 173-82.
Bailey CJ,Day C .2012 .Diabetes therapies in renal impairment. Br J Diabetes Vasc Dis, 12(4) : 167-71.
Yang G,Zeng G,Wu JP .2017 .Glipizide blocks renal interstitial ifbrosis by inhibiting AKT signaling pathway. Eur Rev Med Pharmacol Sci, 21(4) : 867-72.
Erdmann E,Dormandy J,Wilcox R,Massi-Benedetti M .2007 .PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag, 3(4) : 355-70.
Garber AJ,Handelsman Y,Grunberger G,Einhorn D,Abrahamson MJ,Barzilay JI .2020 .Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 Executive Summary. -0472, 26(1) : 107-39.
Alkhail BA,Iftikhar R,Shaikh AA .2016 .Use of Aspirin and Statin as primary prevention for cardiovascular diseases. Pak J Med Sci, 32(6) : 326-9.
Ho CC,Yang YS,Huang CN,Lo SC,Wang YH,Kornelius E. .2022 .2): e0264129. PLoS One, 17 : .